Tex. Ins. Code § 1369.223 · Subchapter E-2. COVERAGE FOR CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
COVERAGE REQUIREMENTS.
Text — Current through the 89th 2nd Called Legislative Session, 2025
A health benefit plan that provides coverage for chimeric antigen receptor T-cell therapy must provide coverage for chimeric antigen receptor T-cell therapy that is:
(1) medically necessary; and
(2) administered by a health care provider that is:
(A) qualified as a certified health care facility in accordance with the procedure for the chimeric antigen receptor T-cell therapy product license approved by the United States Food and Drug Administration; and
(B) participating in the health benefit plan's network with respect to any other service.
Notes and commentary — not statutory text
History
Added by Acts 2025, 89th Leg., R.S., Ch. 608 (H.B. 3057), Sec. 1, eff. September 1, 2025.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/IN/htm/IN.1369.htm
- Text hash
- sha256 1b343e9bfac9a306cbe4699326607ae648898c2c04371b385a9570fa276cbbf9
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.